Its role Owner
Genmab A/S is a Danish biotechnology company focused on the discovery and development of antibody-based therapeutics, primarily for oncology and immune-related diseases. Headquartered in Copenhagen, with operations in Europe, North America, and Asia, the company advances monoclonal and bispecific antibody technologies through in-house research and collaborations. Related entities include Genmab Holding II B.V. and Genmab Finance LLC.
Genmab’s business model centers on proprietary antibody engineering platforms, co-development agreements, and licensing, generating revenue from research funding, milestones, and royalties. Antibodies discovered or developed by Genmab and commercialized with partners include daratumumab (marketed by Janssen, a Johnson & Johnson company, for multiple myeloma), epcoritamab (co-developed and co-commercialized with AbbVie for B-cell lymphomas), tisotumab vedotin (with Seagen for recurrent or metastatic cervical cancer), amivantamab (marketed by Janssen for certain EGFR-mutated lung cancers), and ofatumumab (licensed to Novartis, marketed as Kesimpta for multiple sclerosis). Genmab continues to expand its pipeline across hematologic malignancies and solid tumors through clinical trials and partnerships.
Also known as Genmab Holding II B.V. and Genmab Finance LLC.
chemXplore tracks 1 project involving Genmab.
Phase 1/2 trial will combine an EGFR/LGR5 bispecific antibody with a KRAS G12D inhibitor plus chemotherapy as first‑line treatment for KRAS G12D‑mutant metastatic colorectal cancer.
Phase 3 trial of subcutaneous T‑cell‑engaging bispecific with R‑CHOP cut progression/death risk by 51% in newly diagnosed DLBCL (IPI 2–5); safety consistent with known profiles.
Rina‑S 120 mg/m² Q3W achieved 45.9% ORR and 12.1‑month median DOR in 109 platinum‑resistant ovarian cancer patients; activity seen across FRα expression levels.
Modeling of MajesTEC‑3 trial data estimates a high cure fraction and nearly fourfold median OS benefit for teclistamab plus daratumumab FASPRO versus standard care in relapsed/refractory myeloma.
The trial's sole U.S. primary endpoint—overall survival—did not reach statistical significance; additional results will be submitted for peer review.
First bispecific‑based, chemotherapy‑free second‑line option in Europe after Phase 3 showed major PFS benefit and high complete response rates.
Phase 3 topline: fixed‑duration subcutaneous epcoritamab + lenalidomide significantly reduced progression/death versus R‑GemOx in relapsed/refractory DLBCL; safety consistent with known profiles.
CHMP recommendation follows MajesTEC-3 Phase 3 data showing HR 0.17 for PFS and HR 0.46 for OS at ~3 years in adults with RRMM after ≥1 prior therapy, with manageable safety.
